123 filings
8-K
WVE
Wave Life Sciences Ltd.
6 Mar 24
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:39am
8-K
WVE
Wave Life Sciences Ltd.
8 Jan 24
Regulation FD Disclosure
8:11am
8-K
WVE
Wave Life Sciences Ltd.
4 Jan 24
Other Events
4:07pm
8-K
WVE
Wave Life Sciences Ltd.
15 Dec 23
Regulation FD Disclosure
8:36am
8-K
WVE
Wave Life Sciences Ltd.
7 Dec 23
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
9:26pm
8-K
77996
9 Nov 23
Regulation FD Disclosure
4:27pm
8-K
86kcsfw
9 Nov 23
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
7:39am
8-K
luzukswph gkh
2 Oct 23
Regulation FD Disclosure
7:31am
8-K
d19h5sdovl
28 Sep 23
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
4:38pm
8-K
sx8a5hy8
5 Sep 23
Regulation FD Disclosure
4:05pm
8-K
ug279gllvfex61tm 0r
7 Aug 23
Departure of Directors or Certain Officers
5:01pm
8-K
3h4d0a f2y
3 Aug 23
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
7:37am
8-K
8xgym88drfgn99btv635
23 May 23
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated
7:48am
8-K
xt455xzjrq qu5
3 May 23
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
7:43am
8-K
ssmxppwfv
22 Mar 23
Wave Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
7:36am
8-K
ktjkbo vv
10 Mar 23
Regulation FD Disclosure
5:01pm
8-K
aaulh
30 Jan 23
Entry into a Material Definitive Agreement
8:00am
8-K
2p1nm6z a2kzk
9 Jan 23
Regulation FD Disclosure
8:01am
8-K/A
2mw7hct8
19 Dec 22
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
10:17am
8-K
8l9lzw pr9go5d7boh5
19 Dec 22
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
7:43am